In EGFR wild‐type A549 and H460 cells, the anti‐cancer activity of Ibr‐7 was obviously superior to that of ibrutinib (Fig. 1B), indicating different mechanisms of actions of Ibr‐7. This evidence concerns the gene EGFR and cancer.